| ADC | Antibody–Drug Conjugates |
| ADCC | Antibody–Dependent Cell-mediated Cytotoxicity |
| ADCP | Antibody–Dependent Cellular Phagocytosis |
| APC | Antigen-Presenting Cell |
| CAF | Cancer-Associated Fibroblast |
| CDC | Complement-Dependent Cytotoxicity |
| CAN | Copy Number Alteration |
| CRISPR | Clustered Regularly Interspaced Short Palindromic Repeats |
| CSC | Cancer Stem Cell |
| CTC | Circulating Tumor Cell |
| cfDNA | Circulating cell-free DNA |
| ctDNA | circulating tumor DNA |
| EMA | European Medicines Agency |
| EMT | Epithelial–Mesenchymal Transition |
| FDA | Food and Drug Administration |
| HIF | Hypoxia-Inducible Factor 1 |
| HRE | Hypoxia-Responsive Elements |
| IFN | Interferon |
| THE | Interleukin |
| ITH | Intratumor Heterogeneity |
| mAb | Monoclonal Antibody |
| MMP | Matrix Metalloproteinase |
| MDSC | Myeloid-Derived Suppressor Cell |
| MSC | Mesenchymal Stem Cell |
| NGS | Next Generation Sequencing |
| NFkB | Nuclear Factor kappa B |
| NK | Natural Killer |
| PDGF | Platelet-Derived Growth Factor |
| PGF | Placental Growth Factor |
| SDF-1 | Stromal Cell-Derived Factor 1 |
| TAM | Tumor-Associated Macrophage |
| TGF | Tumor Growth Factor |
| TLR | Toll-Like Receptor |
| TME | Tumor Microenvironment |
| TNF | Tumor Necrosis Factor |
| Treg | T regulatory cell |
| VCAM-1 | Vascular Cellular Adhesion Molecule-1 |
| VEGF | Vascular Endothelial Growth Factor |